Contact
searchSearch
HMP Global
Login

20S Proteasome News

News
High Rate of CR Shown With Monoclonal Antibody REGN5458 for Heavily Pretreated R/R MM
03/03/2022
Nearly half of patients had a complete response with REGN5458, a BCMA-CD3 bispecific antibody monotherapy to treat heavily pretreated R/R MM.
Nearly half of patients had a complete response with REGN5458, a BCMA-CD3 bispecific antibody monotherapy to treat heavily pretreated R/R MM.
Nearly half of patients had a...
03/03/2022
Oncology
News
Isatuximab Plus Pomalidomide and Dexamethasone: New Standard of Care for Relapsed/Refractory MM
03/02/2022
A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.
A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.
A novel combination of...
03/02/2022
Oncology
News
FDA Approves BCMA-Directed CAR-T Immunotherapy for R/R MM
03/01/2022
The FDA has approved ciltacabtagene autoleucel, a novel CAR-T immunotherapy regimen to target BCMA in patients with R/R MM.
The FDA has approved ciltacabtagene autoleucel, a novel CAR-T immunotherapy regimen to target BCMA in patients with R/R MM.
The FDA has approved...
03/01/2022
Oncology
News
Phase 3 CANDOR Trial Confirms Triplet Regimen Improves PFS for R/R MM
02/09/2022
Final analysis results of the phase 3 CANDOR study confirm improved PFS and longer follow-up outcomes of carfilzomib, daratumumab, and dexamethasone for patients with R/R MM.
Final analysis results of the phase 3 CANDOR study confirm improved PFS and longer follow-up outcomes of carfilzomib, daratumumab, and dexamethasone for patients with R/R MM.
Final analysis results of the...
02/09/2022
Oncology
News
Ixazomib Combo With Pomalidomide, Dexamethasone Increases PFS in Patients With R/R MM
01/28/2022
Results from a phase 1/2 study showed adding ixazomib to pomalidomide and dexamethasone as part of a second line therapy increased PFS in patients with R/R MM and warrants future phase III investigations.
Results from a phase 1/2 study showed adding ixazomib to pomalidomide and dexamethasone as part of a second line therapy increased PFS in patients with R/R MM and warrants future phase III investigations.
Results from a phase 1/2 study...
01/28/2022
Oncology
News
Triplet Combo Therapy Provides Limited Toxicity in Relapsed MM
12/02/2021
Phase 2 data were presented at the 2021 ASH Annual Meeting for a subgroup of relapsed patients with MM who had durable responses to ixazomib, lenalidomide, and dexamethasone.
Phase 2 data were presented at the 2021 ASH Annual Meeting for a subgroup of relapsed patients with MM who had durable responses to ixazomib, lenalidomide, and dexamethasone.
Phase 2 data were presented at...
12/02/2021
Oncology
News
20S Proteasome and UCH-L1 Concentrations Investigated as Biomarkers in TCC
10/04/2021
SPRi-based biosensors were used to analyze 20S proteasome and UCH-L1 concentrations in bodily fluids of patients with TCC to understand the relationship between ubiquitin and proteasome and cancer progression.
SPRi-based biosensors were used to analyze 20S proteasome and UCH-L1 concentrations in bodily fluids of patients with TCC to understand the relationship between ubiquitin and proteasome and cancer progression.
SPRi-based biosensors were used...
10/04/2021
Oncology
News
FDA Approves Melphalan Flufenamide for Relapsed/Refractory MM
03/03/2021
The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
The FDA has approved melphalan...
03/03/2021
Oncology
News
FDA Approves New CAR-T Therapy for R/R Large B-Cell Lymphoma
02/19/2021
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
The FDA has approved...
02/19/2021
Oncology
News
Experts Show Potential of miR-100 Against MCL Cell Proliferation
10/06/2020
Findings from a clinical study suggest that miR-100 may be an anti-MCL gene.
Findings from a clinical study suggest that miR-100 may be an anti-MCL gene.
Findings from a clinical study...
10/06/2020
Oncology

Recent News

News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use